HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free All Versions of this Article: 105/2/581    most recent 90484.2008v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Lundby, C. Articles by Calbet, J. A. L. Search for Related Content PubMed PubMed Citation Articles by Lundby, C. Articles by Calbet, J. A. L.

Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport?

¹Copenhagen Muscle Research Centre, Rigshospitalet, Copenhagen, Denmark; ²Department of Sport Science, University of Århus, Århus, Denmark; ³Ecole Nationale de Ski et d'Alpinisme, Chamonix, France; ⁴Department of Exercise Science, Concordia University, Montreal, Quebec, Canada; ⁵Copenhagen Muscle Research Centre, Department of Anaesthesia, Rigshospitalet, Copenhagen, Denmark; ⁶School of Physical Education, Department of Sports Medicine and Exercise Science, University of Athens, Athens, Greece; and ⁷Department of Physical Education, University of Las Palmas de Gran, Canaria, Spain

Submitted 3 April 2008 ; accepted in final form 29 May 2008

This study was performed to test the hypothesis that administration of recombinant human erythropoietin (rHuEpo) in humans increases maximal oxygen consumption by augmenting the maximal oxygen carrying capacity of blood. Systemic and leg oxygen delivery and oxygen uptake were studied during exercise in eight subjects before and after 13 wk of rHuEpo treatment and after isovolemic hemodilution to the same hemoglobin concentration observed before the start of rHuEpo administration. At peak exercise, leg oxygen delivery was increased from 1,777.0 ± 102.0 ml/min before rHuEpo treatment to 2,079.8 ± 120.7 ml/min after treatment. After hemodilution, oxygen delivery was decreased to the pretreatment value (1,710.3 ± 138.1 ml/min). Fractional leg arterial oxygen extraction was unaffected at maximal exercise; hence, maximal leg oxygen uptake increased from 1,511.0 ± 130.1 ml/min before treatment to 1,793.0 ± 148.7 ml/min with rHuEpo and decreased after hemodilution to 1,428.0 ± 111.6 ml/min. Pulmonary oxygen uptake at peak exercise increased from 3,950.0 ± 160.7 before administration to 4,254.5 ± 178.4 ml/min with rHuEpo and decreased to 4,059.0 ± 161.1 ml/min with hemodilution (P = 0.22, compared with values before rHuEpo treatment). Blood buffer capacity remained unaffected by rHuEpo treatment and hemodilution. The augmented hematocrit did not compromise peak cardiac output. In summary, in healthy humans, rHuEpo increases maximal oxygen consumption due to augmented systemic and muscular peak oxygen delivery.

hemoglobin concentration

This article has been cited by other articles:

				J. A. L. Calbet, G. Radegran, R. Boushel, and B. Saltin On the mechanisms that limit oxygen uptake during exercise in acute and chronic hypoxia: role of muscle mass J. Physiol., January 15, 2009; 587(2): 477 - 490. [Abstract] [Full Text] [PDF]

				D. Boning, N. Maassen, and A. Pries No proof for augmented arterial oxygen content as only factor influencing exercise capacity after Epo doping J Appl Physiol, December 1, 2008; 105(6): 1988 - 1988. [Full Text] [PDF]

				C. Lundby Reply to Boning, Maassen, and Pries J Appl Physiol, December 1, 2008; 105(6): 1989 - 1989. [Full Text] [PDF]